Day: April 23, 2025

Coop Pank unaudited financial results for Q1 2025

Written by Customer Service on April 23, 2025. Posted in Earnings Releases And Operating Results.

By the end of the Q1 2025, Coop Pank had 213,000 customers, increased by 5,000 customers in the quarter (+2%) and by 23,000 in the year (+12%). The bank had 101,800 active customers, increased by 2,400 (+3%) in the quarter and by 17,400 (+21%) in the year. In Q1 2025, volume of deposits in Coop Pank decreased by 29 million euros (+2%), reaching total of 1.91 billion euros. Deposits from private clients increasing by 15 million euros: demand deposits increased by 9 million euros and term deposits increased by 6 million euros. Deposits from domestic business customers increased by 39 million euros: demand deposits increased by 36 million euro and term deposits increased by 3 million euros. Deposits from international deposit platform Raisin and other financing decreased by 24 million euros. Compared to Q1 2024, volume of Coop Pank’s...

Corbion announces strong first quarter 2025 results, well on track to deliver full-year outlook

Written by Customer Service on April 23, 2025. Posted in Earnings Releases And Operating Results.

DATE 23 April 2025 Corbion Q1 2025 Interim Management Statement Corbion announces strong first quarter 2025 result, well on track to deliver full-year outlook Corbion, the Amsterdam-listed sustainable ingredients company that champions preservation through application of science, today publishes its results for Q1 2025 ending 31 March.Key highlights Q1 2025:• Organic sales growth: +7.9% ο Volume/mix: +8.4% ο Price: -0.5%• Sales: € 329.7 million• Adjusted EBITDA: € 54.4 million, an organic increase of +53.9%• Operating profit: € 34.0 million, an organic increase of +186%• FY 2025 outlook affirmed€ million Q1 2025 Q1 20241 Total growth Organic growth Sales 329.7 300.4 +9.8% +7.9% Adjusted EBITDA 54.4 34.5 +57.7% +53.9% Adjusted EBITDA...

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

Written by Customer Service on April 23, 2025. Posted in Mergers And Acquisitions.

VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate (“ADC”) and Bispecific T-cell Engager (“TCE”) Candidates, with Strong and Differentiated Clinical Profiles Company Pursuing Multiple Strategic Partnerships and Licensing Opportunities in 2025 and 2026 Transaction Values VERAXA at a Pre-money Equity Value of $1.3 Billion Actively Working with Existing and New VERAXA Investors to Raise a Crossover Financing Round, which is Expected to Close Ahead of the Business Combination, Alongside up to $253 Million in Cash Held in Trust Business Combination is Expected to be Completed in the Fourth Quarter of 2025 A Joint Investor Presentation Providing an Overview of the Proposed Transaction can be Viewed: https://dealroadshow.com/e/VER2025ZURICH,...

Update on Transaction Regulatory Approvals

Written by Customer Service on April 23, 2025. Posted in Mergers And Acquisitions.

BRISBANE, Australia, April 23, 2025 (GLOBE NEWSWIRE) — Sayona Mining Limited (“Sayona” or “Company”) (ASX:SYA; OTCQB:SYAXF) provides an update on the proposed transaction with Piedmont Lithium Inc. (“Piedmont Lithium”) (NASDAQ:PLL, ASX:PLL) (see announcement on 19 November 2024) (the “Transaction”) that will combine the two companies to create a leading lithium business. Subject to Sayona shareholder approval, the name of the Company will be changed to Elevra Lithium Limited (“Elevra Lithium”) upon completion of the Transaction. The Transaction will result in an approximate 50% / 50% equity holding of shareholders of Sayona and Piedmont Lithium (on a fully diluted basis) in Elevra Lithium immediately following the closing of the Transaction. Since the Transaction announcement, significant progress has been made in preparing for...

Northann Corp. Receives NYSE Notice Regarding Late Filing of Annual Report on Form 10-K

Written by Customer Service on April 23, 2025. Posted in Public Companies.

Fort Lawn, SC, April 22, 2025 (GLOBE NEWSWIRE) — Northann Corp. (“Northann” or the “Company”) (NYSE American: NCL), a company specializing in 3D printing and manufacturing solutions, announced today that on April 16, 2025, the Company received a written notice from NYSE Regulation (the “Filing Delinquency Notification”) stating that the Company is not in compliance with the continued listing standards of the NYSE American LLC (“NYSE American”, or the “Exchange”). Specifically, the Company has not met the requirements set forth in Sections 134 and 1101 of the NYSE American Company Guide due to its delayed filings of the Form 10-K for the year ended December 31, 2024 (the “Delinquent Report”) by the filing due date of April 15, 2025 (the “Filing Delinquency”). Reference is made to the Company’s Notification of Late Filing on Form...

OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science

Written by Customer Service on April 23, 2025. Posted in Public Companies.

Poster Presentations featuring the latest advancements on anti-TROP2 ADCs (OBI 992 and OBI 902), AKR1C3 prodrug (OBI-3424), OBI’s novel ADC enabling technologies (GlycOBI® and ThiOBI®), and Globo H science TAIPEI, Taiwan, April 23, 2025 (GLOBE NEWSWIRE) — OBI Pharma, Inc. (TPEx: 4174. TWO) today announced nonclinical data for OBI-902, a potential best-in-class anti-TROP2 ADC developed using the next generation proprietary GlycOBI® technologies. OBI-902 demonstrated superior antitumor activity and favorable PK/PD properties compared to benchmark TROP2 ADCs across various animal models. OBI-992, a cysteine-based TROP2 targeting ADC, demonstrated a differentiated resistance profile compared to benchmark ADCs. Additionally, characterization and non-clinical in vivo data will be presented for the glycan-specific GlycOBI® and cysteine-based...

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Written by Customer Service on April 23, 2025. Posted in Public Companies.

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data during the 2025 Digestive Disease Week (DDW) meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary activity of REC-4881 for the treatment of familial adenomatous polyposis (FAP). The data will be presented as a late-breaking oral presentation during the Research Forum session on Hereditary GI cancer syndromes on Sunday, May 4, 2025 in San Diego. “We are pleased that DDW has recognized the importance of our data in addressing the unmet needs of the FAP patient population, where no FDA-approved therapies currently exist,” said Najat Khan, PhD, Chief R&D Officer and Chief Commercial...

Sonoco Named to USA TODAY America’s Climate Leaders 2025 List

Written by Customer Service on April 23, 2025. Posted in Public Companies.

HARTSVILLE, S.C., April 22, 2025 (GLOBE NEWSWIRE) — Sonoco Products Company (NYSE: SON), a global leader in high-value sustainable packaging, has been named to USA TODAY’s list of America’s Climate Leaders 2025. This prestigious award is presented by USA TODAY and Statista, the world-leading statistics portal and industry ranking provider. The list was announced on April 22, 2025, and can be viewed on usatoday.com. “A continued focus for Sonoco is our commitment to promote accountability and transparency in our sustainability and corporate responsibility programs,” said Howard Coker, president and CEO. “Our simplified portfolio of more sustainable metal and fiber packaging further enhances our commitment to serve as a valued partner to our customers in reducing the environment impacts of their packaging.” The America’s Climate...

Day: April 23, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals